{"groups":[{"description":"Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days).","id":"FG000","title":"Vemurafenib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Progressive disease"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"No follow up required in re-treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"No follow up required in re-treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"36"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"14"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"22"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}